by Team Small News | Jan 15, 2026 | Cipla, Lupin, Pharma, Sun Pharma, Zydus
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in... by Team Small News | Jan 12, 2026 | Lupin, Pharma
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and... by Team Small News | Jan 5, 2026 | Lupin, Pharma
PolyPeptide, a leading manufacturer of peptides, has formed a strategic alliance with Lupin Manufacturing Solutions. The partnership aims to establish a framework for long-term cooperation, focusing on integrated procurement and supply planning for select raw... by Team Small News | Dec 4, 2025 | Lupin, Pharma
The pharmaceutical company, Lupin, is reportedly in discussions to acquire Vitabiotics, a UK-based vitamins and supplements manufacturer, in a deal estimated to be worth £1 billion (approximately Rs 11,800 crore). Vitabiotics is a family-owned brand, founded by the... by Team Small News | Nov 28, 2025 | Lupin, Pharma
The Golden Cross is a technical indicator that suggests a trend reversal from bearish to bullish, occurring when the 50-day moving average (DMA) moves above the 200 DMA. For Lupin, a pharmaceutical company, this event may mark the beginning of a recovery phase after a... by Team Small News | Nov 15, 2025 | Lupin, Pharma
Lupin Limited, a global pharmaceutical company, has achieved a significant milestone by securing an S&P Global ESG Score of 91 for 2025. This score places the company among a select group of pharmaceutical organizations that have crossed the 90-point threshold,...